Subscribe
dna-istock-518143098-ralwel-
Ralwel / iStockphoto.com
17 April 2019Americas

US university treats cancer patients with CRISPR

The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.

More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.

More features

Powell Gilbert co-founder moves to US firm
GSK: ‘Whoever moves first has UPC advantage’
Pfizer and BioNTech win UK COVID-19 dispute
Roche to outside counsel: ‘Law firms must adapt to the modern world’
Astellas defends blockbuster cancer treatment patent
Regeneron denied safe harbour defence in COVID-19 drug dispute
Moderna wins reprieve in COVID-19 vaccine dispute
Boehringer sues Indian manufacturer over diabetes drug generic